Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia
September 21, 2024 04:15 ET
|
Teva Pharmaceutical Industries Ltd
As a leader in neuroscience, Teva is committed to researching new treatment innovations that may help address unmet needs in treating schizophrenia, including TEV-‘749Currently, there is no...
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)
September 21, 2024 04:10 ET
|
Teva Pharmaceutical Industries Ltd
As a leader in neuroscience, Teva remains committed to helping address unmet needs in the treatment of schizophrenia through scientific and clinical advances that support optimal treatment options and...
Host Hotels & Resorts Announces Third Quarter 2024 Earnings Call to be Held on November 7, 2024
September 20, 2024 16:30 ET
|
Host Hotels & Resorts, L.P.
BETHESDA, Md., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Host Hotels & Resorts, Inc. (NASDAQ: HST) (the “Company”), the nation’s largest lodging real estate investment trust, will report third quarter...
Powerback Rehabilitation Announces AI-Powered Partnership with PredictionHealth to Optimize Therapy Operations, Documentation Compliance, and CPT Coding
September 20, 2024 11:07 ET
|
Powerback
Powerback Rehabilitation announces a new strategic partnership with PredictionHealth.
Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC
September 20, 2024 08:30 ET
|
Alpha Tau Medical Ltd.
JERUSALEM, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha...
Canacol Energy Ltd. Announces Revised 2024 Capital Program, Comments on 2024 Guidance and Provides Drilling Update
September 20, 2024 08:00 ET
|
Canacol Energy Ltd.
CALGARY, Alberta, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Canacol Energy Ltd. (“Canacol” or the “Corporation”) (TSX: CNE; OTCQX: CNNEF; BVC: CNEC) announces that it has revised its 2024 capital program,...
Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study
September 20, 2024 05:30 ET
|
Sanofi - Aventis Groupe
Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study Data presented at ECTRIMS...
Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
September 19, 2024 16:30 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Novo Nordisk A/S: Wegovy® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function
September 19, 2024 15:10 ET
|
Novo Nordisk A/S
Wegovy® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function Wegovy® (semaglutide 2.4 mg) is the first...
Perdue Strike Out Hunger Challenge with Delmarva Shorebirds Generates Record 688,000 Meal Equivalents for Hunger Relief
September 19, 2024 12:44 ET
|
Perdue Farms
Salisbury, MD, Sept. 19, 2024 (GLOBE NEWSWIRE) -- As part of Perdue Farms’ commitment to help alleviate food insecurity, the company teamed with the Delmarva Shorebirds Class A minor league baseball...